Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL347681 | 0.98 | CYP1A2 (0.72) | CYP1A2CYP2D6 | |
| SCHEMBL8019304 | 0.86 | CYP1A2 (0.58) | CYP1A2CYP2D6 | |
| SCHEMBL1372 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP2D6 | |
| SCHEMBL4798477 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP2D6 | |
| SCHEMBL5028799 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2D6 | |
| SCHEMBL2597843 | 0.84 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Bromide SCHEMBL22418547 | 0.84 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL21805838 | 0.84 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| SCHEMBL2645833 | 0.84 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2761 | 0.84 | CYP1A2 (0.96) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934934-A2 | Methods of preparing substituted 3-phenyl- and 3-pyridyl-4(3H)-quinazolinones and atropisomers thereof | Pfizer Products Inc. (US) | 1999-08-11 | — | — | EP | claimed |
| US-20250375936-A1 | METHOD FOR MANUFACTURING THREE-DIMENSIONAL OBJECT AND INK SET FOR MANUFACTURING THREE-DIMENSIONAL OBJECT | UNIV OSAKA (JP) | 2025-12-11 | — | — | US | disclosed |
| EP-4578635-A1 | METHOD FOR MANUFACTURING THREE-DIMENSIONAL SHAPED ARTICLE AND INSET FOR PRODUCTION OF THREE-DIMENSIONAL SHAPED ARTICLE | OSAKA UNIVERSITY (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4549131-A1 | METHOD FOR MANUFACTURING THREE-DIMENSIONAL OBJECT AND INK SET FOR MANUFACTURING THREE-DIMENSIONAL OBJECT | OSAKA UNIVERSITY (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119768265-A | Method for producing three-dimensional molded article and ink set for producing three-dimensional molded article | 国立大学法人大阪大学 | 2025-04-04 | — | — | CN | disclosed |
| US-12030963-B2 | Matrices comprising a modified polysaccharide | MAPTECH HOLDINGS UG (DE) | 2024-07-09 | — | — | US | disclosed |
| WO-2024043039-A1 | METHOD FOR MANUFACTURING THREE-DIMENSIONAL SHAPED ARTICLE AND INSET FOR PRODUCTION OF THREE-DIMENSIONAL SHAPED ARTICLE | 国立大学法人大阪大学 | 2024-02-29 | — | — | WO | disclosed |
| EP-4066933-A1 | SYSTEM FOR THE ENCAPSULATION AND CONTROLLED RELEASE OF PYRETHROIDS HAVING EXTENDED EFFICACY OVER TIME AGAINST FRUIT FLY | Fundacion Centro de Innovacion y Demostracion Tecnologica (ES) | 2022-10-05 | — | — | EP | disclosed |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-0446267-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS. | BRITISH BIO TECHNOLOGY (GB) | 1991-09-18 | — | — | EP | disclosed |
| EP-0441517-A2 | Tricyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-5015639-A | Antipsychotic, antidepressive, analgesic | SCHERING CORPORATION (US) | 1991-05-14 | — | — | US | disclosed |
| WO-1991002716-A2 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1991-03-07 | — | — | WO | disclosed |
| US-4994477-A | Hypotensive agents | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
| WO-1990005719-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-05-31 | — | — | WO | disclosed |
| WO-1990005716-A1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-05-31 | — | — | WO | disclosed |
| EP-0357641-A1 | SUBSTITUTED BENZAZEPINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1990-03-14 | — | — | EP | disclosed |
| WO-1988007526-A1 | SUBSTITUTED BENZAZEPINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | CYP1A2 481/4885CYP2D6 1554/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | CYP1A2 481/4885CYP2D6 1554/4885 |
| US-12030963-B2 | Matrices comprising a modified polysaccharide | FUT5, FUT6, CSGALNACT1 | CYP1A2 1596/4885CYP2D6 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.